SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-22-000111
Filing Date
2022-10-04
Accepted
2022-10-04 08:02:29
Documents
13
Period of Report
2022-09-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20220928.htm   iXBRL 8-K 38022
  Complete submission text file 0001599298-22-000111.txt   203454

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20220928.xsd EX-101.SCH 2159
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20220928_def.xml EX-101.DEF 14830
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20220928_lab.xml EX-101.LAB 28736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20220928_pre.xml EX-101.PRE 15427
7 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20220928_htm.xml XML 11091
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 221289764
SIC: 2834 Pharmaceutical Preparations